Transplant conditioning regimens

Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.

Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.

Autologous (auto) stem cell transplant

BEAM

BEAM: BiCNU, Etoposide, Ara-C, Melphalan

Regimen (Stewart, et al. 2006)

Autologous blood stem cells are infused on day 0.

• Carmustine (BiCNU) 300 mg/m2 IV on day -6
• Etoposide (Vepesid) 100 mg/m2 IV Q12H on days -5 to -2 (8 total doses)
• Cytarabine (Cytosar) 200 mg/m2 IV Q12H on days -5 to -2 (8 total doses)
• Melphalan (Alkeran) 140 mg/m2 IV on day -1

Supportive medications:

• Patients <70 kg: Filgrastim (Neupogen) 300 mcg SC daily starting on day +7 after stem cell transplant
• Patients >70 kg (reference did not clarify which dosage to use for patients who are exactly 70 kg): Filgrastim (Neupogen) 480 mcg SC daily starting on day +7 after stem cell transplant
• Trimethoprim/Sulfamethoxazole (Bactrim DS) (160/800 mg) PO BID on Monday and Thursdays, until 6 months after BEAM

While ANC <500

• Ciprofloxacin (Cipro) 500 mg PO BID
• Fluconazole (Diflucan) 100 mg PO daily or mycostatin 500,000 units swish & swallow QID
• Acyclovir (Zovirax) 400 mg PO TID

Alternate regimen (Josting, et al. 2005)

Paper did not specify which day peripheral blood stem cells were administered.

• Carmustine (BiCNU) 300 mg/m2 IV on day 1
• Etoposide (Vepesid) 150 mg/m2 IV Q12H on days 2-5 (8 total doses)
• Cytarabine (Cytosar) 200 mg/m2 IV Q12H on days 2-5 (8 total doses)
• Melphalan (Alkeran) 140 mg/m2 IV on day 1

References

1. Josting A, Sieniawski M, Glossmann JP, Staak O, Nogova L, Peters N, Mapara M, Dörken B, Ko Y, Metzner B, Kisro J, Diehl V, Engert A. High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study. Ann Oncol. 2005 Aug;16(8):1359-65. Epub 2005 Jun 6. link to original article contains protocol PubMed
2. Stewart DA, Bahlis N, Valentine K, Balogh A, Savoie L, Morris DG, Jones A, Brown C, Russell JA. Upfront double high-dose chemotherapy with DICEP followed by BEAM and autologous stem cell transplantation for poor-prognosis aggressive non-Hodgkin lymphoma. Blood. 2006 Jun 15;107(12):4623-7. Epub 2006 Feb 7. link to original article contains protocol PubMed

Allogeneic (allo) stem cell transplant

BEAM

BEAM: BiCNU, Etoposide, Ara-C, Melphalan

Regimen

Day 0 is the day of transplantation.

• Carmustine (BiCNU) 300 mg/m2 IV on day -6
• Etoposide (Vepesid) 200 mg/m2 IV BID on days -5 to -2
• Cytarabine (Cytosar) 200 mg/m2 IV BID on days -5 to -2
• Melphalan (Alkeran) 140 mg/m2 IV on day -1

Supportive medications:

• Filgrastim (Neupogen) 5 mcg/kg SC daily, starting day 7 and continued until engraftment
• GVHD prophylaxis with tacrolimus and methotrexate
• "Prophylactic antibiotics"

References

1. Przepiorka D, van Besien K, Khouri I, Hagemeister F, Samuels B, Folloder J, Ueno NT, Molldrem J, Mehra R, Körbling M, Giralt S, Gajewski J, Donato M, Cleary K, Claxton D, Braunschweig I, Andersson B, Anderlini P, Champlin R. Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma. Ann Oncol. 1999 May;10(5):527-32. link to original article contains protocol PubMed